Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

NCT02869217 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02869217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02869217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 30, 2016
Completion date
November 30, 2026
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, esophageal cancer, liver cancer, lung cancer, melanoma, ny-eso-1 expressing solid tumors in hla-a2 positive patients, ovarian cancer, synovial sarcoma